Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianluca Gaidano

Showing results (1-10 of 541) with videos related to

Pageof 55
Sort By:
Expert Opinion on Therapeutic Targets|November 12, 2025
XPO-1 targeting in chronic lymphocytic leukemia: is there potential for therapeutic strategy?Nawar Maher, Gianluca Gaidano
British Journal of Cancer|April 1, 2016
The clinical implications of gene mutations in chronic lymphocytic leukaemiaDavide Rossi, Gianluca Gaidano
Hematology (Amsterdam, Netherlands)|February 20, 2004
Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosisDavide Rossi, Gianluca Gaidano
BMJ (Clinical Research Ed.)|August 25, 2016
Regulatory agencies should engage in drug pricingRaffaella Ravinetto, Gianluca Gaidano
Haematologica|January 3, 2012
ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matterDavide Rossi, Gianluca Gaidano
Advances in Experimental Medicine and Biology|September 10, 2013
Richter syndromeDavide Rossi, Gianluca Gaidano
Expert Opinion on Investigational Drugs|December 9, 2020
Investigational drugs for the treatment of diffuse large B-cell lymphomaAndrea Patriarca, Gianluca Gaidano
Cancers|October 14, 2022
Richter Syndrome: From Molecular Pathogenesis to Druggable TargetsSamir Mouhssine, Gianluca Gaidano
Blood|March 18, 2021
Intravascular lymphoma: from vessels to genesAndrea Patriarca, Gianluca Gaidano
AIDS (London, England)|January 18, 2011
Tracking the biological risk of coronary artery disease in HIV-infected individuals: the case of circulating endothelial progenitor cellsDavide Rossi, Gianluca Gaidano
Pageof 55

Showing results (1-10 of 541) with videos related to

Sort By:
Pageof 55
Expert Opinion on Therapeutic Targets|November 12, 2025
XPO-1 targeting in chronic lymphocytic leukemia: is there potential for therapeutic strategy?Nawar Maher, Gianluca Gaidano
British Journal of Cancer|April 1, 2016
The clinical implications of gene mutations in chronic lymphocytic leukaemiaDavide Rossi, Gianluca Gaidano
Hematology (Amsterdam, Netherlands)|February 20, 2004
Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosisDavide Rossi, Gianluca Gaidano
BMJ (Clinical Research Ed.)|August 25, 2016
Regulatory agencies should engage in drug pricingRaffaella Ravinetto, Gianluca Gaidano
Haematologica|January 3, 2012
ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matterDavide Rossi, Gianluca Gaidano
Advances in Experimental Medicine and Biology|September 10, 2013
Richter syndromeDavide Rossi, Gianluca Gaidano
Expert Opinion on Investigational Drugs|December 9, 2020
Investigational drugs for the treatment of diffuse large B-cell lymphomaAndrea Patriarca, Gianluca Gaidano
Cancers|October 14, 2022
Richter Syndrome: From Molecular Pathogenesis to Druggable TargetsSamir Mouhssine, Gianluca Gaidano
Blood|March 18, 2021
Intravascular lymphoma: from vessels to genesAndrea Patriarca, Gianluca Gaidano
AIDS (London, England)|January 18, 2011
Tracking the biological risk of coronary artery disease in HIV-infected individuals: the case of circulating endothelial progenitor cellsDavide Rossi, Gianluca Gaidano
Pageof 55